Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
11.26.2007
Oncology to outgrow global pharma market
A new report from bionest partners outlines future trends of the oncology market. The area of oncology is posed for high growth, with Roche/Genentech to lead the pack - however strong competition to be expected. Biologics will be one of the main growth drivers with pricing and market access challenges ahead.
No comments:
Post a Comment